Lysosome dysfunction in podocytopathy and associated hypertension
足细胞病和相关高血压中的溶酶体功能障碍
基本信息
- 批准号:9792379
- 负责人:
- 金额:$ 48.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-25 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:AbbreviationsAgonistAlbuminuriaAnimal ModelApplications GrantsAutophagocytosisAutophagosomeBloodBlood VesselsCalmodulinCardiovascular DiseasesCardiovascular systemCell Differentiation processCell physiologyCeramidesCodeDefectDevelopmentDiabetes MellitusDiffuseDiseaseEnd stage renal failureEnterobacteria phage P1 Cre recombinaseEnzymesExcretory functionExtravasationFarber&aposs lipogranulomatosisFocal Segmental GlomerulosclerosisFoot ProcessFunctional disorderGene DeletionGenesHeartHyperhomocysteinemiaHypertensionImageInjuryInterleukin-13KidneyLeadLipidsLongevityLysosomesMediatingMembrane ProteinsMetabolismModelingMolecularMouse StrainsMultivesicular BodyMusNephrotic SyndromeObesityPathogenesisPathogenicityPathologicPatientsPhenotypePreventionProcessProteinsProteinuriaRegulationRenal functionRenal glomerular diseaseReportingResearchRoleSclerosisSignal PathwaySignal TransductionSphingolipidsSphingomyelinsSphingosineStructureTestingTransmission Electron MicroscopyUrinebasecell typeexosomegalactosylgalactosylglucosylceramidaseglomerulosclerosisknockout genemouse modelnovelpatch clamppodocytepreventreceptorsensortherapeutic targettrafficking
项目摘要
Project Summary
Podocytopathy is an important pathogenic basis for different glomerular diseases such as minimal change
disease (MCD), diffuse mesangial sclerosis, focal segmental glomerulosclerosis, collapsing glomeru-
lonephropathy and global glomerulosclerosis associated with hyperhomocysteinemia (hHcy), obesity and
diabetes mellitus. These glomerular diseases have been reported to account for the vast majority of end-stage
renal disease and kidney-associated hypertension and cardiovascular diseases. Recent studies have indicated
that normal autophagy is a critical cellular process to control podocyte function and even its life span and that
deficient autophagy and associated autophagosome (AP) accumulation or increases in exosome release
produce podocyte injury and podocytopathy. We have shown that a sphingolipid-mediated signaling pathway is
importantly implicated in lysosome dysfunction, autophagic flux deficiency and ultimate podocytopathy and
glomerular sclerosis. The present grant proposal will test a central hypothesis that lysosomal acid ceramidase
(AC)-mediated sphingolipid metabolism critically controls lysosome trafficking or fusion to APs or multivesicular
body (MVB) and subsequent degradation process determining the normal phenotype and function of
podocytes. AC gene defect or functional deficiency may disturb lysosome degradation of APs and MVBs,
which induces AP accumulation and exosome release from MVBs leading to podocyte phenotypic transition,
effacement and ultimate MCD. To test this hypothesis, three Specific Aims are proposed. Specific Aim 1 will
determine whether autophagic flux and exosome excretion in podocytes are fine controlled by lysosomal AC
activity and whether the deficiency of this AC regulation causes podocytopathy and MCD in Asah1fl/fl/Podocre
mice, but not in their littermates. Specific Aim 2 attempts to elucidate the central role of lysosomal AC-
mediated sphingolipid signaling in the regulation of lysosome trafficking to and fusion with APs and MVBs for
their degradation using podocyte-specific Asah1 gene deletion, rescuing and silencing. In Specific Aim 3, we
will explore the mechanisms by which lysosome trafficking or fusion in podocytes is regulated by AC-
associated sphingolipids via gating lysosomal TRPML1 channels and associated Ca2+ release using patch
clamping of isolated lysosomes and lysosome-specific Ca2+ imaging with GCaMP3-ML as an indicator. These
proposed studies will present a novel mouse model for podocytopathy and MCD and use this model to explore
associated molecular mechanisms triggering podocytopathy. The grant proposal represents the first effort in
the research field to investigate the AC-mediated lysosome regulation of autophagic flux and exosome
excretion in podocytes and associated pathogenic role in potocytopathy. The findings may make paradigm shift
in understanding pathogenesis of podocytopathy and MCD and help identify lysosomal AC as a therapeutic
target for prevention or treatment of MCD and other glomerular diseases.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PinLan Li其他文献
PinLan Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PinLan Li', 18)}}的其他基金
Lysosome dysfunction in podocytopathy and associated hypertension
足细胞病和相关高血压中的溶酶体功能障碍
- 批准号:
10461007 - 财政年份:2018
- 资助金额:
$ 48.89万 - 项目类别:
Lysosome dysfunction in podocytopathy and associated hypertension
足细胞病和相关高血压中的溶酶体功能障碍
- 批准号:
10218151 - 财政年份:2018
- 资助金额:
$ 48.89万 - 项目类别:
Lysosome Trafficking Dysregulation of Arterial Myocytes in Atherogenesis
动脉粥样硬化中动脉肌细胞的溶酶体运输失调
- 批准号:
9097883 - 财政年份:2015
- 资助金额:
$ 48.89万 - 项目类别:
Renomedullary metabolism of anandamide and blood pressure regulation
anandamide 的肾髓代谢与血压调节
- 批准号:
9054518 - 财政年份:2015
- 资助金额:
$ 48.89万 - 项目类别:
Lysosome Trafficking Dysregulation of Arterial Myocytes in Atherogenesis
动脉粥样硬化中动脉肌细胞的溶酶体运输失调
- 批准号:
9201339 - 财政年份:2015
- 资助金额:
$ 48.89万 - 项目类别:
Lysosome Trafficking Dysregulation of Arterial Myocytes in Atherogenesis
动脉粥样硬化中动脉肌细胞的溶酶体运输失调
- 批准号:
9002899 - 财政年份:2015
- 资助金额:
$ 48.89万 - 项目类别:
Epigenetic Regulation of Lysosomal Ceramide Signaling and Function in Arterial Myocytes: Role of Kmt6 Gene
动脉肌细胞溶酶体神经酰胺信号和功能的表观遗传调控:Kmt6 基因的作用
- 批准号:
10450193 - 财政年份:2014
- 资助金额:
$ 48.89万 - 项目类别:
Renomedullary metabolism of anandamide and blood pressure regulation
anandamide 的肾髓代谢与血压调节
- 批准号:
8852753 - 财政年份:2014
- 资助金额:
$ 48.89万 - 项目类别:
Lysosome Trafficking Dysregulation of Arterial Myocytes in Atherogenesis
动脉粥样硬化中动脉肌细胞的溶酶体运输失调
- 批准号:
8842197 - 财政年份:2014
- 资助金额:
$ 48.89万 - 项目类别:
Epigenetic Regulation of Lysosomal Ceramide Signaling and Function in Arterial Myocytes: Role of Kmt6 Gene
动脉肌细胞溶酶体神经酰胺信号和功能的表观遗传调控:Kmt6 基因的作用
- 批准号:
10666405 - 财政年份:2014
- 资助金额:
$ 48.89万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 48.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 48.89万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 48.89万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 48.89万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 48.89万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 48.89万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 48.89万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 48.89万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 48.89万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 48.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




